Table 3 Demographics, clinical characteristics, treatments, prognosis, and relapse of patients with IATM grouped according to their clinical outcome

Age at onset (years)

53.5(41~62)

43(31~65)

0.443

Sex, female

47(58.8%)

16(59.3%)

0.963

Time from onset to first MRI (days)

7.5(3~12)

3(1~9)

0.008*

Time from onset to maximum deficit (days)

5(2.3~10.0)

3(2~12)

0.724

Preceding infection or immunization

11(13.8%)

4(14.8%)

1.000

Back/neck pain

15(18.8%)

8(29.6%)

0.234

Sensory disturbance

72(90.0%)

24(88.9%)

1.000

Limb weakness

48(60.0%)

26(96.3%)

<0.001*

Sphincter dysfunction

29(36.3%)

18(66.7%)

0.006*

Signs of upper motor neuron injury

29(36.3%)

11(40.7%)

0.677

Spinal shock

23(28.8%)

13(48.1%)

0.065

Second-line therapies(PLEX or IVIg)

12(15.0%)

17(63.0%)

<0.001*

Length of hospital stays (days)

13(10~17.8)

18(13~25)

0.004*

Follow-up duration (months)

32(18~47)

36(22~48)

0.362

ICU admission

0(0.0%)

2(7.4%)

0.062

Complication

15(18.8%)

9(33.3%)

0.116

Relapse

10(12.5%)

5(18.5%)

0.647

EDSS at nadir

3.5(2~7)

8.5(6.5~9.0)

<0.001*

EDSS at follow-up

1(1~2)

5(5~7)

<0.001*

MRI-positive

42(52.5%)

22(81.5%)

0.008*